我们采用SEER-Medicare对2008年至2017年间诊断为外周T细胞淋巴瘤（PTCL）的年龄在65岁以上的患者进行了一项基于人群的研究。我们使用Kaplan-Meier方法和多变量Cox回归分析了PTCL亚型、治疗方案、共病症与死亡率之间的关联。在2,546名患者中，中位年龄为77岁（四分位数范围为71-83岁）。根据PTCL亚型不同，5年总生存率（OS）在22.2%至37.3%之间。最常用的一线治疗方案是环磷酰胺、多柔比星、长春新碱和泼尼松（CHOP）。etoposide + CHOP（N = 67；CHOEP）治疗的患者5年OS率为47.0%，CHOP治疗的患者（N = 732）为33.7%，无蒽环类药物的治疗方案（N = 105）为23.8%（p < 0.001）。在没有共病症的患者中，CHOEP治疗仍与改善的OS相关（HR 0.52, 95% CI, 0.30-0.91）。从使用二线治疗开始，中位OS为1.2年（N = 228），与治疗方案无关。一线治疗方案而非二线治疗方案与PTCL患者的OS有关。

We conducted a population-based study of patients >65 years, diagnosed 2008-2017, with peripheral T-cell lymphoma (PTCL) using SEER-Medicare. Associations between PTCL subtype, treatment regimen, comorbidity, and mortality were assessed using the Kaplan-Meier method and multivariable Cox regression. Amongst the 2,546 patients, the median age was 77 years (interquartile range, 71-83). 5-year overall survival (OS) ranged from 22.2% to 37.3% depending on PTCL subtype. The most common frontline regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). 5-year OS rate was 47.0% for patients treated with etoposide + CHOP (N = 67; CHOEP), 33.7% for those treated with CHOP (N = 732), and 23.8% for patients treated with non-anthracycline-containing regimens (N = 105; p < 0.001). In patients without comorbidities, CHOEP remained independently associated with improved OS (HR 0.52, 95% CI,0.30-0.91). Median OS was 1.2 years from initiation of second-line therapy (N = 228) independent of treatment regimen. Frontline but not second-line treatment regimen is associated with OS in older patients with PTCL.